Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,801–6,900 of 15,747
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study
Novak, J., & Potemkin, V. (2022) · Molecular Diversity · doi:10.1007/s11030-021-10355-8 · Cited by 13
Kosiorek, P., Kazberuk, D., Hryniewicz, A., Milewski, R. J., Stróż, S., & Stasiak‐Barmuta, A. (2022) · Vaccines · doi:10.3390/vaccines10020334 · Cited by 10
Gisondi, P., Geat, D., Naldi, L., & Piaserico, S. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17200 · Cited by 11
Kaczmarek, R., Ekiaby, M. E., Hart, D. P., Hermans, C. R. J. R., Makris, M., Noone, D., O’Mahony, B. W., Page, D., Peyvandi, F., Pipe, S. W., et al. (2021) · Haemophilia · doi:10.1111/hae.14271 · Cited by 11
Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential
New, J., Shenton, L. M., Ksayer, R., Wang, J., Zakharia, K., Nicholson, L. J., & Pandey, A. C. (2024) · Vaccines · doi:10.3390/vaccines12111270 · Cited by 15
“SARS-CoV-2 mRNA vaccines result in an initial cytokine response of IFN-γ , IL-2 and IL-4, alongside an antibody and T-cell response, which result in durable clinical protection against infection, though for a limited amount of time [28,29].”
Figa, Z., Temesgen, T., Getnet, A., Ganta, M., Alemu, A., Abebe, M., & Ashuro, Z. (2022) · Public Health in Practice · doi:10.1016/j.puhip.2022.100343 · Cited by 11
“Once more, the effectiveness of those vaccines were around 95% in preventing SARS COV-2 infection throughout different age group, sex, race, ethnicity, baseline BMI, the presence of coexisting conditions, and the reduction of hospital admission [9][10].”
What Gastroenterologists Should Know About COVID-19 Vaccines
Rolak, S. C., Hayney, M. S., Farraye, F. A., Temte, J. L., & Caldera, F. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.01.001 · Cited by 11
COVID-19 Vaccine Hesitancy among Health Care Workers in the Middle East Region
Aoun, A. H., Aon, M. H., Alshammari, A. Z., & Moussa, S. A. (2021) · The Open Public Health Journal · doi:10.2174/1874944502114010352 · Cited by 10
“Current vaccines confer 62-95% protection rate at best [8, 10].”
BackgroundCOVID-19 vaccines and women's security
Harman, S., Herten-Crabb, A., Morgan, R., Smith, J., & Wenham, C. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32727-6 · Cited by 15
Sisay, M. M., Guevara, C. M. M., Osman, A. K., Saraswati, P. W., Tilahun, B. C., Ayele, T. A., Ahmadizar, F., Durán, C. E., Sturkenboom, M., van de Ven, P. M., et al. (2023) · Vaccines · doi:10.3390/vaccines11061035 · Cited by 15
“Moreover, according to literatures [6,7,40,48,49], the most known side effects of COVID-19 vaccines are mild and temporary, but they should be continuously monitored and evaluated.”
Rhodes, S., Smith, N., Evans, T. G., & White, R. G. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.012 · Cited by 12
“For the RNA vaccine, BNT162b2 (Pfizer vaccine), the chosen dose, 30ug (52), was within the IQR of the predicted RNA optimal doses found in Objective 2 for the overall population and the elderly population.”
Vassallo, M., Clement, N., Lotte, L., Manni, S., Sindt, A., Bertrand, P. M., & Durant, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.809154 · Cited by 10
Sarwar, R., Adeyi, O. A., Lake, J. R., et al. (2022) · Liver Transplantation · doi:10.1002/lt.26446 · Cited by 11
Kratzer, B., Schlax, L. C., Gattinger, P., Waidhofer‐Söllner, P., Trapin, D., Tauber, P. A., Sehgal, A. N. A., Körmöczi, U., Rottal, A., Feichter, M., et al. (2022) · Allergy · doi:10.1111/all.15406 · Cited by 11
“11,12,14 The following preexisting medical conditions were inquired for: Cardiovascular diseases, chronic lung diseases, allergy/asthma, diabetes mellitus, hematopoietic diseases, immunosuppressive conditions, liver diseases, metabolic diseases, neurological disorders, or renal diseases. c…”
Sakayori, M., Hagiwara, E., Baba, T., Kitamura, H., Sekine, A., Ikeda, S., Tabata, E., Yamada, S., Fujimoto, K., & Ogura, T. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.09.006 · Cited by 11
“Another finding of this study is that, as indicated in Table 2, the incidence of all adverse reactions to the COVID-19 vaccines other than respiratory symptoms did not appear to be any clearly higher in patients with ILD than previously reported from clinical trials [1,2], although the age and background of the popula…”
ResultAbarca, K., V, Iturriaga, C., Urzua, M. D., Corre, N. L., Pineda, A., Fernández, C., Domínguez, A., González, P. A., Bueno, S. M., Donato, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10071082 · Cited by 11
“The low reactogenicity profile of CoronaVac® contrasts with the relatively high incidence of local and systemic AEs reported post-vaccination for other vaccine platforms, such as mRNA and adenoviral vectors, with pain observed in 50–80%, fever in 16–51%, fatigue in up to 70%, and myalgias in up to 60% of the participa…”
BackgroundCOVID-19 signalome: Potential therapeutic interventions
Lundstrom, K. H., Hromić‐Jahjefendić, A., Bilajac, E., Aljabali, A. A. A., Baralić, K., Sabri, N. A., Shehata, E. M., Raslan, M., Raslan, S. A., Ferreira, A. C. B. H., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110559 · Cited by 12
Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in SwitzerlandPreprint
Shattock, A. J., Rutte, E. A. L., Dünner, R. P., Sen, S., Kelly, S. L., Chitnis, N., & Penny, M. A. (2021) · medRxiv · doi:10.1101/2021.04.14.21255503 · Cited by 11
Pai, M., Tung, K., Hsu, S., Peng, Y., Lin, W., Yang, J., Wu, H., Chiu, Y., Shu, K.-H., & Tsai, W. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2172432 · Cited by 9
“This is in contrast to reported profiles of mRNA vaccines where the reactogenicity increased with the second dose [19,20].”
ResultTang, G., Westover, K. D., & Jiang, S. B. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.666599 · Cited by 11
Kuitunen, I., Uimonen, M., Seppälä, S., & Ponkilainen, V. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12993 · Cited by 10
Research progress of mRNA vaccines for infectious diseases
Zhang, Z., Du, J., Zhang, D., Han, R., Wu, X., & Liang, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03060-x · Cited by 24
“This research indicated that the occurrence of severe adverse events post-vaccination was minimal and not substantially different from the placebo cohort, demonstrating the vac-cine’s safety [142].”
Dündar, B., Karahangil, K., ELGORMUS, C. S., & Topsakal, H. N. H. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27649 · Cited by 14
Sherman, A. C., Desjardins, M., & Baden, L. R. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.008 · Cited by 11
“For example, the clinical protection from BNT162 against COVID-19 may start as soon as 12 days after the first dose.(82) However, nAb titers within the first 21 days after vaccination are low or undetectable.”
Bieńkowski, C., Skrzat‐Klapaczyńska, A., Firląg‐Burkacka, E., Horban, A., & Kowalska, J. D. (2023) · Vaccines · doi:10.3390/vaccines11030514 · Cited by 11
“Nevertheless, there were no separate analyses regarding vaccines’ safety and efficacy in this specific subgroup of patients [15,17].”
BackgroundRadhwi, O., Jan, H., Waheeb, A., Alamri, S. S., Alahwal, H. M., Denetiu, I., Almanzlawey, A., Al-Marzouki, A. F., Almohammadi, A. T., Bahashwan, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10020151 · Cited by 10
“These vaccines include Oxford–AstraZeneca ChAdOx1 nCoV-19 vaccine (AZD1222) [4] and Pfizer–BioNTech mRNA COVID-19 vaccine (BNT162b2) [5], which gained early access in Saudi Arabia, then followed by the Moderna mRNA SARS-CoV-2 vaccine (mRNA-1273) [6].”
BackgroundVestibular neuronitis after COVID-19 vaccination
Bramer, S., Jaffe, Y., & Sivagnanaratnam, A. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-247234 · Cited by 11
Engineering Hybrid Extracellular Vesicles for Functional mRNA Delivery
Louro, A. F., Gomes, I., Lu, C., Alfonzo‐Méndez, M. A., Dekker, N., Khan, M., & Lázaro‐Ibáñez, E. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509636 · Cited by 15
Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation
Olmedillas, E., Rajamanickam, R. R., Avalos, R. D., Ana-Sosa-Batiz, F., Zyla, D., Zandonatti, M. A., Harkins, S. S., Shresta, S., Hastie, K. M., & Saphire, E. O. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116052 · Cited by 19
(2022) · doi:10.3390/v14040800 · Cited by 9
“For instance, with the Pfizer vaccine, protection against symptomatic COVID-19 was only at 52% twelve days after the first dose [8].”
BackgroundImmunization schedule of the Pediatric Spanish Association: 2022 recommendations
García, F. J. Á., Ortega, M. J. C., Aldeán, J. Á., Garcés‐Sánchez, M., Llanos, E. G., de Arce, A. I., Melián, A. M., Gómez, M. L. N., Solas, V. P., Calle, I. R., et al. (2022) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2021.11.002 · Cited by 15
Alter, G., Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-200342/v1 · Cited by 10
SARS-CoV-2 Vaccine Breakthrough Infections of Omicron and Delta Variants in Healthcare Workers
Regenhardt, E., Kirsten, H., Weiß, M., Lübbert, C., Stehr, S. N., Remane, Y., Pietsch, C., Hönemann, M., & von Braun, A. (2023) · Vaccines · doi:10.3390/vaccines11050958 · Cited by 13
“While the initial results for the vaccine Comirnaty (BNT162b2) by BioNTech/Pfizer showed an efficacy against symptomatic infection of approximately 95% in phase III studies, the appearance of new SARS-CoV-2 variants in combination with waning immunity over time have led to an increased occurrence of SARS-CoV-2 vaccine…”
ResultDubé, C., Paris‐Robidas, S., Andreani, G., Gutzeit, C., D’Aoust, M., Ward, B. J., & Trépanier, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.046 · Cited by 13
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine
Follmann, D. A., Mateja, A., Fay, M. P., Magaret, C. A., Huang, Y., Fong, Y., Angier, H. E., Nason, M., Gay, C. L., Kotloff, K. L., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae081 · Cited by 11
Urakawa, R., Isomura, E. T., Matsunaga, K., & Kubota, K. (2022) · Vaccines · doi:10.3390/vaccines10081357 · Cited by 11
“It has been reported that adverse reactions occur more frequently and are more severe after the second dose than after the first, in females than in males, and in younger than in older vaccine recipients [14,15], which we previously described with a multivariate analysis report [16].”
BackgroundSong, L., Liu, H., Brinkman, F. S. L., Gill, E. E., Griffiths, E., Hsiao, W., Kallesøe, S. S., Moreira, S., Domselaar, G. V., Zawati, M. H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.716541 · Cited by 14
Bauernfeind, S., Huppertz, G., Mueller, K., Hitzenbichler, F., Hardmann, L., Pemmerl, S., Hollnberger, H., Sieber, W., Wettstein, M., Seeliger, S., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac203 · Cited by 12
Montoya, B., Melo‐Silva, C. R., Tang, L., Kafle, S., Lidskiy, P., Bajusz, C., Vadovics, M., Muramatsu, H., Ábrahám, E., Lipinszki, Z., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.019 · Cited by 14
Role of interleukin-6 in antigen-specific mucosal immunoglobulin A induction by cationic liposomes
Tada, R., Hidaka, A., Tanazawa, Y., Ohmi, A., Muto, S., Ogasawara, M., Saito, M., Ohshima, A., Iwase, N., Honjo, E., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108280 · Cited by 11
Naleway, A. L., Grant, L., Caban-Martinez, A. J., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12956 · Cited by 11
mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates
Waickman, A. T., Victor, K., Newell, K. L., Li, T., Friberg, H., Foulds, K. E., Roederer, M., Bolton, D. L., Currier, J. R., & Seder, R. A. (2022) · JCI Insight · doi:10.1172/jci.insight.160039 · Cited by 12
“4 140 mRNA-based vaccine platforms – such as Moderna’s mRNA-1273 and Pfizer/BioNTech’s BNT162b2 – 141 which encode a stabilized version of the SARS-CoV-2 spike glycoprotein (23) show >90% efficacy 142 against symptomatic COVID-19 in initial Phase 3 analyses and in large-scale prospective studies 143 performed after th…”
Novel insights into the pathogenesis and treatment of NRAS mutant melanoma
Zhao, J. W., Galvez, C., Beckermann, K. E., Johnson, D. B., & Sosman, J. A. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1938545 · Cited by 12
Yalcin, D., Bennett, S. J., Sheehan, J., Trauth, A. J., Tso, F. Y., West, J. T., Hagensee, M. E., Ramsay, A. J., & Wood, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087292 · Cited by 12
“Two of the most effective and frequently administered COVID-19 vaccines are the Pfizer/BioNTech BNT162b2 [12] and Moderna/NIAID mRNA-1273 [13] mRNA-based vaccines, which encode a membrane-anchored stabilized S protein through modification of two Pro mutations in the prefusion conformation [14].”
BackgroundInfluentialBeaudoin-Bussières, G., Chen, Y.-Z., Ullah, I., Prévost, J., Tolbert, W., Symmes, K., Ding, S.-L., Benlarbi, M., Gong, S., Tauzin, A., et al. (2021) · bioRxiv · doi:10.1101/2021.09.08.459408 · Cited by 15
Lu, D. Z., Aleta, A., Ajelli, M., Pastor‐Satorras, R., Vespignani, A., & Moreno, Y. (2021) · medRxiv · doi:10.1101/2021.03.19.21253974 · Cited by 16
Lazarus, R., Taucher, C., Brown, C., Ramljak, I. C., Danon, L., Dubischar, K. L., Duncan, C. J. A., Eder-Lingelbach, S., Faust, S. N., Green, C., et al. (2021) · medRxiv · doi:10.1101/2021.08.13.21262021 · Cited by 14
Matsuura, R., Kawamura, A., Matsumoto, Y., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10091796 · Cited by 11
“In addition, various vaccines and antiviral drugs have also been developed to prevent viral propagation and disease progression [4,5].”
BackgroundLi, M., Long, J., Wang, X., Liao, Y., Liu, Y., Hao, Y., Wu, Q., Zhou, Y., Wang, Y., Wang, Y., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.782501 · Cited by 13
“” Public’s personal stigma attitudes were measured by the following nine questions: (1) If I were him, I would prefer to keep people from knowing about my situation; (2) I’m not willing to provide home service (such as delivery) for him or visit his home; (3) I think that he was affected by the disease because of his…”
BackgroundSerologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients
Hoffman, T. W., Meek, B., Rijkers, G. T., & van Kessel, D. A. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101599 · Cited by 16
Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients
Romano, E., Pascolo, S., & Ott, P. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002932 · Cited by 11
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 13
“However, while vaccines can induce sufficiently potent bnAbs against SARS-CoV-2 [182-184], and COVID-19 convalescent individuals acquire protective immunity through natural infection [185], it has not been possible to induce broadly protective Abs by HIV-1 vaccines [76] and primary HIV-1 infection does not adequately…”
BackgroundMinami, S., Kotaki, T., Sakai, Y., Okamura, S., Torii, S., Ono, C., Motooka, D., Hamajima, R., Nouda, R., Nurdin, J. A., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02859-23 · Cited by 10
Piñana, J. L., Vázquez, L., Martino, R., de la Cámara, R., Sureda, A. M., Rodríguez‐Veiga, R., Garrido, A., Sierra, J., Ribera, J., Torrent, A., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1992619 · Cited by 11
Maher, S., assaly, N. M. E., Aly, D. M., Atta, S. A., Fteah, A. M., Badawi, H., Zahran, M. Y., & Kamel, M. M. (2024) · Virology Journal · doi:10.1186/s12985-024-02546-0 · Cited by 12
“In clinical trials, the BNT162b2 vaccine showed 95% protection against COVID-19 following two doses [12].”
BackgroundInfluentialO’Connor, D. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2093193 · Cited by 13
mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma
Tusup, M., Läuchli, S., Jarzębska, N. T., French, L. E., Chang, Y., Eisenring, M., Su, A. A. H., Kündig, T. M., Guenova, E., & Pascolo, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071040 · Cited by 13
“During the COVID-19 pandemic, the mRNA vaccines were the first to be tested in humans as a prophylaxis against SARS-CoV-2 infection and the first to be approved [11].”
BackgroundWei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., & Zhai, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524317 · Cited by 25
Nappi, F., Iervolino, A., & Singh, S. (2021) · Metabolites · doi:10.3390/metabo11060341 · Cited by 13
Gerhard, A., Raeder, V., Pernice, H. F., Boesl, F., Schroeder, M., Richter, J., Endres, M., Prüß, H., Hahn, K., Audebert, H. J., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11895-9 · Cited by 16
“Initially, all approved vaccines were found to be safe, with generally mild and transient side effects such as pain on the injection site, fever, or headache [17].”
BackgroundSøndergaard, M. H., Thavarajah, J. J., Henson, H. C., & Wejse, C. M. (2023) · HIV Medicine · doi:10.1111/hiv.13537 · Cited by 13
“COVID-19 vaccines are the main measure for reducing the severity and mortality of SARS-CoV-2 [8-10].”
BackgroundCOH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants
Wussow, F., Kha, M., Faircloth, K., Nguyen, V. H., Iniguez, A., Martinez, J., Park, Y., Nguyen, J., Kar, S., Andersen, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104457 · Cited by 13
“The ongoing emergence of SARS-CoV-2 VOC with mutant spike (S) proteins poses imminent challenges to establish protective immunity by approved firstgeneration COVID-19 vaccines (Polack et al., 2020; Baden et al., 2021; Voysey et al., 2021; Sadoff et al., 2021), which were antigenically designed based on the Wuhan-Hu-1…”
BackgroundGulati, G. K., Simpson, A., MacMillen, Z., Krieger, K., Sharma, S., Erasmus, J. H., Reed, S. G., Davie, J. W., Avril, M., & Khandhar, A. P. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.023 · Cited by 14
Chua, T. H., & Takano, A. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216290 · Cited by 12
“regimen of Pfizer-BioNTech was 95% effective in preventing COVID-19 [4], although a decline in vaccine efficacy to 91.”
BackgroundSouza, M. S., Farias, J. P., Andreata‐Santos, R., Silva, M. P., Brito, R. D. D. S., da Silva, M. D. B., Peter, C. M., Cirilo, M. V. D. F., Luiz, W. B., Birbrair, A., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29416 · Cited by 12
“11,12 The bivalent vaccine (COMINARTY Original/Omicron BA.4 ‐ 5 COVID ‐ 19 vaccine) used as a booster shot was mainly a fifth dose after monovalent ‐ based vaccine regimens.”
BackgroundA comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort studyPreprint
Anscombe, C., Lissauer, S., Thole, H., Rylance, J., Dula, D., Menyere, M., Kutambe, B., van der Veer, C., Phiri, T., Banda, N. P., et al. (2022) · medRxiv · doi:10.1101/2022.02.17.22269742 · Cited by 15
“The early release of the Wuhan-1 genome sequence (5) enabled the development of specific diagnostic tests (6) and the design of mRNA vaccines, used to such great success in high-income countries (7,8).”
BackgroundArāja, D., Krūmiņa, A., Nora-Krūkle, Z., Berķis, U., & Murovska, M. (2022) · Vaccines · doi:10.3390/vaccines10122115 · Cited by 11
Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia
Pfrepper, C., Holstein, K., Königs, C., Heller, C., Krause, M., Olivieri, M., Bidlingmaier, C., Sigl-Kraetzig, M., Wendisch, J., Halimeh, S., et al. (2021) · Hämostaseologie · doi:10.1055/a-1401-2691 · Cited by 11
Uncovering the gender health data gap
di Lego, V. (2023) · Cadernos de Saúde Pública · doi:10.1590/0102-311xen065423 · Cited by 16
“This generates a gender health data gap that impacts all branches and levels of health research, including disease prevention and diagnosis, medical treatment for cancer, cardiovascular and Alzheimer’s disease 2,3 .”
BackgroundSidlow, J. S., Reichel, M., & Lowenstein, E. J. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.05.018 · Cited by 11
Adjusting extracellular pH to prevent entry of SARS-CoV-2 into human cells
Wang, B. (2021) · Genome · doi:10.1139/gen-2020-0167 · Cited by 11
Reacciones adversas asociadas a vacunas contra la COVID-19
Morales, N. A., Gómez-Henao, C., Calle, A., Villa, R. C., Zuluaga, L. S. D., Santamaría-Salazar, L. C., Ramírez-Giraldo, R. H., Chinchilla, C., & Sánchez, J. M. (2021) · CES Medicina · doi:10.21615/cesmedicina.6282 · Cited by 17
“El estudio de fase III de la vacuna de Pfizer fue publicado en diciembre de 2020 (8) y reporta los resultados de la aleatorización 1:1 de 43 448 personas para recibir placebo o la vacuna.”
BackgroundInfluentialFischer, C., Willscher, E., Paschold, L., Gottschick, C., Klee, B., Diexer, S., Bosurgi, L., Dutzmann, J., Sedding, D., Frese, T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00815-1 · Cited by 13
Lièvre, G., Sicsic, J., Galmiche, S., Charmet, T., Fontanet, A. L., & Mueller, J. E. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.024 · Cited by 14
Decrypting the Immune Symphony for RNA Vaccines
Weidensee, B., & Sahu, I. (2025) · Vaccines · doi:10.3390/vaccines13080882 · Cited by 14
Collatuzzo, G., Lodi, V., Feola, D., Palma, G. D., Sansone, E., Sala, E., Janke, C., Castelletti, N., Porru, S., Spiteri, G., et al. (2022) · Viruses · doi:10.3390/v14122657 · Cited by 11
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers
Sansone, E., Sala, E., Tiraboschi, M. M., Albini, E., Lombardo, M., Indelicato, A. M., Rosati, C., Boniotti, M. B., Castelli, F., & Palma, G. D. (2021) · La Medicina del Lavoro · doi:10.23749/mdl.v112i3.11747 · Cited by 11
“HCWs were vaccinated with a two-dose (21-day interval) schedule of BNT162b2 vaccine (Pfizer®), which had shown an efficacy of 95% in the prevention of COVID-19 (2).”
MethodBaradaran, H. R., Dehghanbanadaki, H., Moradpour, F., Eshrati, B., Moradi, G., Azami, M., Ghadery, A. H., Nejad, M.-M. M., & Moradi, Y. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2102001 · Cited by 11
“Messenger RNA (mRNA) based vaccines, BNT162b2 and mRNA-1273, were the first approved vaccines in the United States, revealing about 94% efficacy in preventing the symptomatic coronavirus disease 2019 (COVID- 19) cases [1,2].”
BackgroundResultInfluentialThe Physiologic Response to COVID-19 Vaccination
(2021) · doi:10.1101/2021.05.03.21256482 · Cited by 11
Fu, J. Y. L., Pukhari, M. H., Bador, M. K., Sam, I., & Chan, Y. F. (2023) · Viruses · doi:10.3390/v15040844 · Cited by 11
“5%) of the post-COVID-19 individuals were vaccinated with the BNT vaccine, an mRNA-based vaccine that encodes for the full length spike protein [42], our data indicated that the vaccine could robustly induce CD4+ and CD8+ responses against spike.”
BackgroundNeu, J., del Moral, T., Guthrie, S. O., Hudak, M. L., Indrio, F., Kim, J. H., Kronström, A., Martin, C. R., Modi, N., Rastad, J., et al. (2026) · Pediatric Research · doi:10.1038/s41390-026-04826-7 · Cited by 11
Lu, R., Liang, K.-H., Chiang, H.-L., Hsu, F., Lin, H.-T., Chen, W.-Y., Ke, F.-Y., Kumari, M., Chou, Y., Tao, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15587 · Cited by 12
“LNP-mediated delivery is a key aspect of the successful implementation of mRNA-based vaccines; BNT162b2 and mRNA-1273 each show > 94% efficacy for preventing COVID-19 and have received EUAs in many countries [31, 32, 33].”
COVID-19 Outcomes Among People With HIV and COVID-19 in New York City
Braunstein, S., Wahnich, A., & Lazar, R. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad311 · Cited by 12
The dynamics of quantitative SARS‐CoV‐2 antispike IgG response to BNT162b2 vaccination
Kaneko, S., Kurosaki, M., Sugiyama, T., Takahashi, Y., Yamaguchi, Y., Nagasawa, M., & Izumi, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27231 · Cited by 10
“Early studies on mRNA vaccines from BioNTech/Pfizer and Moderna showed high efficacy and safety.(9,10) Also, more promising reports on the effectiveness of the vaccines after completing the full vaccination schedule (prime and boost dose) have been published.”
BackgroundMethodPreparation of targeted lipid nanoparticles for precision nucleic acid delivery
Geisler, H. C., Battistini, E., Thatte, A. S., Padilla, M. S., & Mitchell, M. J. (2026) · Nature Protocols · doi:10.1038/s41596-025-01330-w · Cited by 24
Aoki, R., Nihei, Y., Matsuzaki, K., Suzuki, H., Kihara, M., Ogawa, A., Nishino, T., Sanada, S., Yokote, S., Okabe, M., et al. (2024) · Kidney360 · doi:10.34067/kid.0000000000000498 · Cited by 14
Immune Responses in SARS-CoV-2, SARS-CoV, and MERS-CoV Infections: A Comparative Review
Irani, S. (2022) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_429_20 · Cited by 13
Abdellatif, A. A. H., Bouazzaoui, A., Tawfeek, H. M., & Younis, M. A. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.113930 · Cited by 13
Aviña, A. E., Paz, D. D., Huang, S.-C., Chen, K., Chang, Y., Lee, C.-M., Lin, C.-H., Wei, F., & Wang, A. Y. L. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.02.016 · Cited by 14
Beck, E. C., Georgieva, M. V., Wang, W., Gómez-Liévano, A., Wang, H., Gao, Y., Kopel, H., Bausch-Jurken, M. T., Patterson‐Lomba, O., Mu, F., et al. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2466726 · Cited by 9
“The searches yielded six studies with evidence on BNT162b2 that were assessed for suitability of an unanchored ITC: Polack et al. 8 , Thomas et al. 37 , Frenck et al. 38 , Moreira et al. 39 , Zou et al. 40 , and Gayed et al. 41 .”
Activity-based epidemic propagation and contact network scaling in auto-dependent metropolitan areas
Kumar, N., Oke, J. B., & Nahmias–Biran, B.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-01522-w · Cited by 11
Measures to Prevent and Control COVID-19 in Skilled Nursing Facilities: A Scoping Review
Canter, B. E., Ulytė, A., McGarry, B. E., & Barnett, M. L. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5175 · Cited by 13
Prada, L. S.-D., Martínez-García, A. M., González-Fernández, B., Gutiérrez-Ballesteros, J., Rojo‐Rello, S., Pérez, S. G., Álvaro‐Meca, A., de Lejarazu, R. O., Sanz-Muñoz, I., & Bouza, J. M. E. (2024) · Scientific Reports · doi:10.1038/s41598-023-50335-6 · Cited by 13
Koike, R., Sawahata, M., Nakamura, Y., Nomura, Y., Katsube, O., Hagiwara, K., Niho, S., Masuda, N., Tanaka, T., & Sugiyama, K. (2022) · Vaccines · doi:10.3390/vaccines10030451 · Cited by 12
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.